4 Topic Commentaries

A Rare Case of Acute Hemolysis After Rasburicase Infusion

• 

  Jacqueline B. Broadway-Duren, Not specified in source

  Oncology

  •

  The University of Texas MD Anderson Cancer Center

  Based on the patient's positive urine bilirubin test (Table 1), elevated total serum bilirubin level of 9.6 mg/dL (Table 2), and anemia with a hemoglobin of 10.7 g/dL (Table 3), it was concluded that the patient was experiencing hemolysis, likely induced by the administration of rasburicase.

  Source
• 

  Luai Madanat, Not specified in source

  Internal Medicine

  •

  William Beaumont Hospital

  Rasburicase-induced methemoglobinemia and haemolysis are documented side effects that occur due to the production of hydrogen peroxide, an oxidative agent, during conversion of uric acid to allantoin.

  Source
• 

  Garrett B. Sherwood, Not specified in source

  Internal Medicine

  •

  University of Alabama at Birmingham

  Rasburicase for the treatment of tumor lysis syndrome has been associated with hemolytic anemia and methemoglobinemia, usually in patients with G6PD deficiency. Risks and benefits should be considered prior to use of rasburicase in at‐risk patients. Methylene blue will worsen the hemolytic anemia in G6PD deficiency and should be avoided.

  Source
• 

  Moeed Ahmed, Not specified in source

  Internal Medicine

  •

  Creighton University School of Medicine

  Methemoglobinemia can occur as a rare complication of treatment with rasburicase, primarily in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

  Source